The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy drug candidate, deferring the decision to review information the biotech submitted after a negative advisory committee vote.
The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy drug candidate, deferring the decision to review information the biotech submitted after a negative advisory committee vote.
